Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
| 9.395 | |
| 9.61 | |
| - | |
| 9.83 | |
| 9.36 | |
| 2.41-12.22 | |
| 675 M | |
| 71 872 K | |
| 0 | |
| 2.391 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare envir...
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week: upgrades for Dupont, Datadog and NetApp. InvestingPro subscribers always get first dibs on ma...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
